Co-processing: Co-Precipitation Technology (CPT) for the Enhancement of Flowability and Bulk Density-Case Studies & Whitepapers-End-to-end CDMO | Porton Pharma Solutions

Case Studies & Whitepapers2025-03-13

The PROTAC technology, through an innovative mechanism of "degradation rather than inhibition," provides a new pathway for targeting traditionally undruggable proteins and addressing resistance issues.

Case Studies & Whitepapers2025-02-10

Antibody-drug conjugates (ADCs) consist of three parts: antibody, linker, and payload. This special combination enables ADCs to selectively target tumor cells and release cytotoxic drugs, but they face many stability challenges during manufacture, storage, and clinical use. In this paper, the drug product development team at Porton (hereinafter referred to as "we") discusses the necessary clinical in-use stability studies for ADCs.